Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Polyphor AG    POLN   CH0106213793

POLYPHOR AG

(POLN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
03/15/2019 03/18/2019 03/19/2019 03/20/2019 03/21/2019 Date
20.3(c) 20.1(c) 19.86(c) 20.65(c) 21.45(c) Last
11 191 5 618 14 575 4 381 3 233 Volume
+1.50% -0.99% -1.19% +3.98% +3.87% Change
More quotes
Financials (CHF)
Sales 2019 14,0 M
EBIT 2019 -43,7 M
Net income 2019 -69,0 M
Finance 2019 85,9 M
Yield 2019 -
Sales 2020 7,54 M
EBIT 2020 -42,9 M
Net income 2020 -51,4 M
Finance 2020 44,4 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 10,8x
EV / Sales2020 25,5x
Capitalization 237 M
More Financials
Company
Polyphor AG is a Switzerland-based company, which is engaged in the development of novel antibiotics and other efficacious therapies. The Company's medicines pipeline includes Murepavadin (POL7080), a novel class of specific outer membrane protein targeting antibiotic to treat resistant Pseudomonas... 
Sector
Pharmaceuticals
Calendar
04/12 | 09:00amShareholder meeting
More about the company
Surperformance© ratings of Polyphor AG
Trading Rating : Investor Rating :
More Ratings
Latest news on POLYPHOR AG
03/15POLYPHOR : announces financial results for the full-year 2018
EQ
03/08NOVO NORDISK : UK biotech bags 1.5m grant for new antibiotic class
AQ
02/07POLYPHOR : Awarded $5.6M Grant from CARB-X
AQ
02/04POLYPHOR : awarded grant from CARB-X of up to $5.6M to support development of no..
EQ
2018POLYPHOR : announces positive results from the FDA Type B Guidance meeting on th..
EQ
2018POLYPHOR : wins the Swiss Technology Award 2018
EQ
2018POLYPHOR : Balixafortide combination with eribulin in metastatic breast cancer d..
EQ
2018POLYPHOR : announces protocol agreement with the FDA for the second pivotal Phas..
EQ
2018POLYPHOR : CMDO Debra Barker to leave Polyphor; Frank Weber to assist in the tra..
EQ
2018POLYPHOR : to present new survival data for balixafortide at the 2018 European S..
EQ
More news
Sector news : Biopharmaceuticals
01:55aEISAI : starts phase 3 trials for second Alzheimer's drug after first's failure
RE
01:38aUPS eyes in-home health services with U.S. vaccine project
RE
03/21JOHNSON & JOHNSON : J&J to record $700 million charge related to abandoned drug ..
RE
03/21JOHNSON & JOHNSON : J&J to Impair Value of Investigational Antiviral Treatment A..
DJ
03/21CONATUS PHARMACEUTICALS : Shares Plummet After Emricasan Study Misses Primary En..
DJ
More sector news : Biopharmaceuticals
Chart POLYPHOR AG
Duration : Period :
Polyphor AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POLYPHOR AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 55,5  CHF
Spread / Average Target 159%
Managers
NameTitle
Giacomo di Nepi Chief Executive Officer
Argeris N. Karabelas Chairman
Kalina Scott Chief Financial Officer
Daniel Obrecht Chief Scientific Officer
Frank Weber Director, Chief Medical & Development Officer
Sector and Competitors
1st jan.Capitalization (M$)
POLYPHOR AG20.24%239
BIOGEN-24.60%63 063
CSL LIMITED4.90%62 436
ALEXION PHARMACEUTICALS37.85%29 422
SAMSUNG BIOLOGICS CO LTD--.--%20 652
GRIFOLS3.28%16 700